Hyperhomocysteinemia in renal transplant recipients

Allon Friedman, Irwin H. Rosenberg, Jacob Selhub, Andrew S. Levey, Andrew G. Bostom

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Renal transplantation is a commonly performed curative procedure for end-stage renal disease. With the increase in renal allograft half-lives, attention is now being focused on cardiovascular morbidity and death in the renal transplant recipient (RTR) population. Among the more novel cardiovascular disease (CVD) risk factors for which this group is at risk is hyperhomocysteinemia. Hyperhomocysteinemia has been associated with an increased risk of CVD, although prospective randomized trials designed to prove causality are still ongoing. Since plasma total homocysteine levels are inversely related to renal function, RTRs have a greatly increased prevalence of hyperhomocysteinemia. Other determinants of homocysteine include B-vitamins, albumin, age, and genetic polymorphisms. Although RTRs are resistant to the typical B-vitamin doses used to correct hyperhomocysteinemia in the general population, they do respond to supraphysiologic dose therapy. In terms of prevalence, etiology, and treatment of hyperhomocysteinemia, RTRs are very similar to the much larger chronic renal insufficiency population. For this reason, RTRs have been chosen as an ideal study population in investigating the effect of reducing hyperhomocysteinemia on CVD outcomes.

Original languageEnglish (US)
Pages (from-to)308-313
Number of pages6
JournalAmerican Journal of Transplantation
Volume2
Issue number4
DOIs
StatePublished - Apr 2002
Externally publishedYes

Fingerprint

Hyperhomocysteinemia
Kidney
Vitamin B Complex
Cardiovascular Diseases
Homocysteine
Population
Genetic Polymorphisms
Chronic Renal Insufficiency
Causality
Kidney Transplantation
Chronic Kidney Failure
Allografts
Transplant Recipients
Albumins
Morbidity
Therapeutics

Keywords

  • Cardiovascular disease
  • Homocysteine
  • Kidney
  • Renal transplant

ASJC Scopus subject areas

  • Immunology

Cite this

Hyperhomocysteinemia in renal transplant recipients. / Friedman, Allon; Rosenberg, Irwin H.; Selhub, Jacob; Levey, Andrew S.; Bostom, Andrew G.

In: American Journal of Transplantation, Vol. 2, No. 4, 04.2002, p. 308-313.

Research output: Contribution to journalArticle

Friedman, Allon ; Rosenberg, Irwin H. ; Selhub, Jacob ; Levey, Andrew S. ; Bostom, Andrew G. / Hyperhomocysteinemia in renal transplant recipients. In: American Journal of Transplantation. 2002 ; Vol. 2, No. 4. pp. 308-313.
@article{5a864d07c0a549ec88351144406ea4ad,
title = "Hyperhomocysteinemia in renal transplant recipients",
abstract = "Renal transplantation is a commonly performed curative procedure for end-stage renal disease. With the increase in renal allograft half-lives, attention is now being focused on cardiovascular morbidity and death in the renal transplant recipient (RTR) population. Among the more novel cardiovascular disease (CVD) risk factors for which this group is at risk is hyperhomocysteinemia. Hyperhomocysteinemia has been associated with an increased risk of CVD, although prospective randomized trials designed to prove causality are still ongoing. Since plasma total homocysteine levels are inversely related to renal function, RTRs have a greatly increased prevalence of hyperhomocysteinemia. Other determinants of homocysteine include B-vitamins, albumin, age, and genetic polymorphisms. Although RTRs are resistant to the typical B-vitamin doses used to correct hyperhomocysteinemia in the general population, they do respond to supraphysiologic dose therapy. In terms of prevalence, etiology, and treatment of hyperhomocysteinemia, RTRs are very similar to the much larger chronic renal insufficiency population. For this reason, RTRs have been chosen as an ideal study population in investigating the effect of reducing hyperhomocysteinemia on CVD outcomes.",
keywords = "Cardiovascular disease, Homocysteine, Kidney, Renal transplant",
author = "Allon Friedman and Rosenberg, {Irwin H.} and Jacob Selhub and Levey, {Andrew S.} and Bostom, {Andrew G.}",
year = "2002",
month = "4",
doi = "10.1034/j.1600-6143.2002.20404.x",
language = "English (US)",
volume = "2",
pages = "308--313",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Hyperhomocysteinemia in renal transplant recipients

AU - Friedman, Allon

AU - Rosenberg, Irwin H.

AU - Selhub, Jacob

AU - Levey, Andrew S.

AU - Bostom, Andrew G.

PY - 2002/4

Y1 - 2002/4

N2 - Renal transplantation is a commonly performed curative procedure for end-stage renal disease. With the increase in renal allograft half-lives, attention is now being focused on cardiovascular morbidity and death in the renal transplant recipient (RTR) population. Among the more novel cardiovascular disease (CVD) risk factors for which this group is at risk is hyperhomocysteinemia. Hyperhomocysteinemia has been associated with an increased risk of CVD, although prospective randomized trials designed to prove causality are still ongoing. Since plasma total homocysteine levels are inversely related to renal function, RTRs have a greatly increased prevalence of hyperhomocysteinemia. Other determinants of homocysteine include B-vitamins, albumin, age, and genetic polymorphisms. Although RTRs are resistant to the typical B-vitamin doses used to correct hyperhomocysteinemia in the general population, they do respond to supraphysiologic dose therapy. In terms of prevalence, etiology, and treatment of hyperhomocysteinemia, RTRs are very similar to the much larger chronic renal insufficiency population. For this reason, RTRs have been chosen as an ideal study population in investigating the effect of reducing hyperhomocysteinemia on CVD outcomes.

AB - Renal transplantation is a commonly performed curative procedure for end-stage renal disease. With the increase in renal allograft half-lives, attention is now being focused on cardiovascular morbidity and death in the renal transplant recipient (RTR) population. Among the more novel cardiovascular disease (CVD) risk factors for which this group is at risk is hyperhomocysteinemia. Hyperhomocysteinemia has been associated with an increased risk of CVD, although prospective randomized trials designed to prove causality are still ongoing. Since plasma total homocysteine levels are inversely related to renal function, RTRs have a greatly increased prevalence of hyperhomocysteinemia. Other determinants of homocysteine include B-vitamins, albumin, age, and genetic polymorphisms. Although RTRs are resistant to the typical B-vitamin doses used to correct hyperhomocysteinemia in the general population, they do respond to supraphysiologic dose therapy. In terms of prevalence, etiology, and treatment of hyperhomocysteinemia, RTRs are very similar to the much larger chronic renal insufficiency population. For this reason, RTRs have been chosen as an ideal study population in investigating the effect of reducing hyperhomocysteinemia on CVD outcomes.

KW - Cardiovascular disease

KW - Homocysteine

KW - Kidney

KW - Renal transplant

UR - http://www.scopus.com/inward/record.url?scp=0036556161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036556161&partnerID=8YFLogxK

U2 - 10.1034/j.1600-6143.2002.20404.x

DO - 10.1034/j.1600-6143.2002.20404.x

M3 - Article

VL - 2

SP - 308

EP - 313

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 4

ER -